// App-Quantinova.ai

1439 : Pharmacokinetic Results Of a Feasibility and Phase II Study (ITCC 021) On Bortezomib (BTZ) In Pediatric Relapsed ALL: Lack Of Significant Penetration Of BTZ In The Cerebrospinal Fluid

Researchers

Presenter

  • Gertjan Kaspers

Principal Investigators

  • Ron Mathot

  • Satianand Ramnarain

  • Denise Niewerth

  • Franco Locatelli

  • Eveline S.J.M De Bont

  • Franca Fagioli

  • Pierre Rohrlich

  • Arend von Stackelberg

  • Michel Zwaan

Medical Centers

  • Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands

  • University of Franche-Comte, Besancon, France

  • Pediatric Oncology/Hematology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands

  • Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands

  • Pediatric Oncology/Hematology, Charite Universitatsmedizin Berlin, Berlin, Germany

  • Oncoematologia-Centro Trapianti, Oncoematologia-Centro Trapianti, Ospedale Infantile Regina Margherita, Torino, Italy

  • Pediatric Hematology/Oncology and Transfusion Medicine, IRCCS Bambino Ges Childrens Hospital, Rome, Italy

  • Dept. of Hospital Pharmacy, AMC, Amsterdam, Netherlands

  • Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands

Locations

  • France

  • Germany

  • Italy

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Multiple Myeloma

  • Solid malignancies

Biomarkers

  • Breakpoint Cluster Region

  • Cerebrospinal fluid

Drug/Treatment

  • Glucocorticoid

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Methotrexate

  • Vincristine

  • Bortezomib

  • Allopurinol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved